00:01
All right, so here, given that estic unimab, upregulates the activity of infat, that is, nuclear factor of activated t cells, we need to consider the role of infat in the immune system.
00:18
In fat is a transcription factor, meaning that it upregulates transcription in the cells.
00:27
It specifically activates t cells, normally in the production of cytokines and the differentiation of t cells.
00:36
So we have t -regs, which help maintain immune tolerance and prevent autoimmunity.
00:46
And they're characterized by the expression of foxp3.
00:57
So infat has been shown to be involved in the induction of foxp3, which is crucial for the development of t -regs.
01:04
So now we can look at our answer choices and conclude that the most likely immunologic consequence of using s2 kinamab, given that it upregulates in fat would be increased production of regulatory t cells...